Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

BACKGROUND: Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG)....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Lee, Eudocia Q., Reardon, David A., Schiff, David, Drappatz, Jan, Muzikansky, Alona, Grimm, Sean A., Norden, Andrew D., Nayak, Lakshmi, Beroukhim, Rameen, Rinne, Mikael L., Chi, Andrew S., Batchelor, Tracy T., Hempfling, Kelly, McCluskey, Christine, Smith, Katrina H., Gaffey, Sarah C., Wrigley, Brendan, Ligon, Keith L., Raizer, Jeffrey J., Wen, Patrick Y.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2015
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4483124/
https://ncbi.nlm.nih.gov/pubmed/25572329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou350
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky